London · Delayed Price · Currency is GBP · Price in GBX PureTech Health Statistics
Total Valuation
PureTech Health has a market cap or net worth of GBP 280.00 million. The enterprise value is 268.29 million.
| Market Cap | 280.00M |
| Enterprise Value | 268.29M |
Important Dates
The last earnings date was Tuesday, September 22, 2026.
| Earnings Date | Sep 22, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
PureTech Health has 245.18 million shares outstanding. The number of shares has increased by 2.26% in one year.
| Current Share Class | 245.18M |
| Shares Outstanding | 245.18M |
| Shares Change (YoY) | +2.26% |
| Shares Change (QoQ) | +2.83% |
| Owned by Insiders (%) | 3.85% |
| Owned by Institutions (%) | 70.07% |
| Float | 146.08M |
Valuation Ratios
The trailing PE ratio is 193.48.
| PE Ratio | 193.48 |
| Forward PE | n/a |
| PS Ratio | 58.16 |
| PB Ratio | 0.98 |
| P/TBV Ratio | 0.96 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 167.77 |
| EV / Sales | 55.72 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.60, with a Debt / Equity ratio of 0.59.
| Current Ratio | 4.60 |
| Quick Ratio | 4.38 |
| Debt / Equity | 0.59 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1.48 |
Financial Efficiency
Return on equity (ROE) is 0.38% and return on invested capital (ROIC) is -6.91%.
| Return on Equity (ROE) | 0.38% |
| Return on Assets (ROA) | -10.79% |
| Return on Invested Capital (ROIC) | -6.91% |
| Return on Capital Employed (ROCE) | -17.65% |
| Weighted Average Cost of Capital (WACC) | 8.37% |
| Revenue Per Employee | 53,303 |
| Profits Per Employee | 17,704 |
| Employee Count | 90 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, PureTech Health has paid 3.25 million in taxes.
| Income Tax | 3.25M |
| Effective Tax Rate | 75.08% |
Stock Price Statistics
The stock price has decreased by -12.96% in the last 52 weeks. The beta is 0.81, so PureTech Health's price volatility has been lower than the market average.
| Beta (5Y) | 0.81 |
| 52-Week Price Change | -12.96% |
| 50-Day Moving Average | 117.46 |
| 200-Day Moving Average | 124.31 |
| Relative Strength Index (RSI) | 49.68 |
| Average Volume (20 Days) | 727,580 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, PureTech Health had revenue of GBP 4.80 million and earned 1.59 million in profits. Earnings per share was 0.01.
| Revenue | 4.80M |
| Gross Profit | -44.52M |
| Operating Income | -77.47M |
| Pretax Income | 4.33M |
| Net Income | 1.59M |
| EBITDA | -76.31M |
| EBIT | -77.47M |
| Earnings Per Share (EPS) | 0.01 |
Balance Sheet
The company has 174.50 million in cash and 167.87 million in debt, with a net cash position of 6.63 million or 0.03 per share.
| Cash & Cash Equivalents | 174.50M |
| Total Debt | 167.87M |
| Net Cash | 6.63M |
| Net Cash Per Share | 0.03 |
| Equity (Book Value) | 286.02M |
| Book Value Per Share | 1.20 |
| Working Capital | 148.83M |
Cash Flow
In the last 12 months, operating cash flow was -63.03 million and capital expenditures -4,522, giving a free cash flow of -63.04 million.
| Operating Cash Flow | -63.03M |
| Capital Expenditures | -4,522 |
| Depreciation & Amortization | 1.16M |
| Net Borrowing | -2.64M |
| Free Cash Flow | -63.04M |
| FCF Per Share | -0.26 |
Margins
| Gross Margin | n/a |
| Operating Margin | -1,614.82% |
| Pretax Margin | 90.29% |
| Profit Margin | 33.21% |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
PureTech Health does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -2.26% |
| Shareholder Yield | -2.26% |
| Earnings Yield | 0.57% |
| FCF Yield | -22.59% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for PureTech Health is 300.65, which is 163.27% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | 300.65 |
| Price Target Difference | 163.27% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (3Y) | 93.72% |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
PureTech Health has an Altman Z-Score of 0.8 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.8 |
| Piotroski F-Score | 1 |